Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added to the page, and the funding-status notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding affecting updates was added, and the page revision tag was updated from v3.4.0 to v3.4.1, to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdditions include showing glossary and revision/version labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0); Deletions remove the previous lowercase QC label (Last Update Submitted that met QC Criteria), No FEAR Act data, and an older revision stamp (Revision: v3.3.4). These are minor metadata/label changes and do not affect core study content such as results, eligibility criteria, or key dates; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no substantive changes to the study details are visible.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations section now lists District of Columbia and New Jersey as study sites. The revision label is updated to Revision: v3.3.3.SummaryDifference0.3%

- Check92 days agoChange DetectedPublications section wording now states automatic population from PubMed and the page revision is updated to v3.3.2, replacing the previous wording and revision v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.